RxDoctor Payments Data

George Lee, MD

Family Medicine · Bellevue, WANPI 1972642130

Payments from drug & device makers

$7,958in general payments, 2019–2025

Across 349 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$687
  • Amgen$667
  • AbbVie$666
  • AstraZeneca$665
  • Novo Nordisk$652
  • Johnson & Johnson$526
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$7,71797%
  • Education$2413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,958 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$59,711
Medicare patients
95
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$64,871
OzempicSemaglutide40$51,973
TrulicityDulaglutide33$31,484
JanuviaSitagliptin Phosphate28$30,848
JardianceEmpagliflozin25$29,208
Synjardy XrEmpagliflozin/Metformin Hcl15$12,391
FarxigaDapagliflozin Propanediol15$12,087
CreonLipase/Protease/Amylase12$8,942
ValacyclovirValacyclovir Hcl29$3,019
Rosuvastatin Calcium326$2,745
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$2,565
Gabapentin102$2,243
Albuterol Sulfate HfaAlbuterol Sulfate45$2,152
Levothyroxine Sodium274$1,889
Losartan Potassium259$1,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$354$64,87174 claims
Novo NordiskOzempic$652$51,97340 claims
Boehringer IngelheimJardiance, Synjardy Xr$138$41,59840 claims
Lilly USA, LLCTrulicity$687$31,48433 claims
MerckJanuvia$221$30,84828 claims
AstraZenecaFarxiga$665$12,08715 claims
AbbVieCreon$666$8,94212 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$34$2,56513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →